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Abstract
Objectives To provide a comprehensive overview of all re-
ported cardiac magnetic resonance (CMR) findings that pre-
dict clinical deterioration in pulmonary arterial hypertension
(PAH).
Methods MEDLINE and EMBASE electronic databases
were systematically searched for longitudinal studies
published by April 2015 that reported associations be-
tween CMR findings and adverse clinical outcome in
PAH. Studies were appraised using previously developed
criteria for prognostic studies. Meta-analysis using ran-
dom effect models was performed for CMR findings in-
vestigated by three or more studies.
Results Eight papers (539 patients) investigating 21 different
CMR findings were included. Meta-analysis showed that right
ventricular (RV) ejection fraction was the strongest predictor of
mortality in PAH (pooled HR 1.23 [95 % CI 1.07–1.41],
p=0.003) per 5 % decrease. In addition, RVend-diastolic vol-
ume index (pooled HR 1.06 [95 % CI 1.00–1.12], p=0.049),
RVend-systolic volume index (pooled HR 1.05 [95%CI 1.01–
1.09], p=0.013) and left ventricular end-diastolic volume index
(pooled HR 1.16 [95%CI 1.00–1.34], p=0.045) were of prog-
nostic importance. RVand LV mass did not provide prognostic
information (p=0.852 and p=0.983, respectively).
Conclusion This meta-analysis substantiates the clinical yield
of specific CMR findings in the prognostication of PAH pa-
tients. Decreased RV ejection is the strongest and most well
established predictor of mortality.
Key Points
• Cardiac magnetic resonance imaging is useful for prognos-
tication in pulmonary arterial hypertension.
• Right ventricular ejection fraction is the strongest predictor
of mortality.
• Serial CMR evaluation seems to be of additional prognostic
importance.
• Accurate prognostication can aid in adequate and timely
intensification of PAH-specific therapy.
Keywords Pulmonary arterial hypertension . Prognosis .
Magnetic resonance imaging .Meta-analysis . Mortality
Abbreviations
CMR Cardiac magnetic resonance imaging
HR Hazard ratio
LV Left ventricle/left ventricular
PA Pulmonary artery
PAH Pulmonary arterial hypertension
PH Pulmonary hypertension
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Introduction
Pulmonary arterial hypertension (PAH) is defined as a mean
pulmonary arterial pressure ≥25 mmHg in the presence of a
pulmonary capillary wedge pressure ≤15 mmHg as assessed
by right heart catheterization, and is characterized by progres-
sive remodelling of the distal pulmonary arteries [1]. PAH
includes apparent heterogeneous conditions (idiopathic, heri-
table, induced by drugs or toxins, associated with connective
tissue diseases, HIV infection, portal hypertension and con-
genital heart disease), but is characterized by similar clinical,
haemodynamic and pathological pictures [1, 2]. Left untreat-
ed, the resultant increase in pulmonary vascular resistance
leads to progressive deterioration of right ventricular (RV)
function and eventually death in 45% of incident cases within
3 years [2, 3]. Although recent advances in therapeutic mo-
dalities have significantly improved the outcomes of this dev-
astating disease, the course of the disease widely varies be-
tween individuals [4–6]. In order to guide optimal clinical
management of patients with PAH, accurate prognostication
and monitoring of disease progression is therefore of great
importance [5].
Previously reported predictors of mortality include
aetiology of PAH, sex and several functional, biochemical
and haemodynamic variables [3, 7–10]. Although it is inferred
that cardiac magnetic resonance imaging (CMR) could be of
important additional value, evidence for the prognostic merit
of specific imaging findings is still far from robust. This study
therefore aims to provide a comprehensive overview of com-
monly investigated CMR findings that are predictive of ad-
verse clinical outcome in PAH.
Methods
This systematic review was conducted in accordance with the
PRISMA statement [11]. A pre-defined review protocol as
adopted by this study can be accessed through PROSPERO
(registration number: CRD42014009231).
Literature search strategy
CMR studies as described in this review were identified
through a general search syntax that was designed to aggre-
gate all studies concerning the prognostic value of non-
invasive imaging in PAH. A comprehensive systematic search
was performed on 29 April 2015 in MEDLINE (via PubMed
interface) and EMBASE electronic databases using combina-
tions of all synonyms for: population (PAH), non-invasive
imaging and relevant clinical outcomes (components of the
Dana Point Time To Clinical Worsening composite endpoint)
[2, 12]. A validated prognostic search filter with the highest
sensitivity (98 %) was added to the search syntax [13, 14]. No
language or publication period restrictions were applied. The
full original search syntax is supplied in Supplemental File 1.
Selection of papers
A flow diagram of the selection process is shown in Fig. 1
[11]. After deduplication, one author (VB) performed screen-
ing and selection of articles based on title and abstract, using
the following exclusion criteria: cross-sectional study design,
study population without PH (e.g. acute pulmonary embolism,
exercise-induced PH), >30% study populationwith other than
WHO group I PAH, inclusion of children <12 years of age,
CMR findings not investigated as a potential predictor for
clinical outcome, lack of Cox regression analysis. Full-text
screening was performed by two authors (VB, JH); exclusion
criteria are described in Fig. 1. All references of the excluded
reviews and included articles were cross-checked to identify
possible relevant articles missed in the original search syntax.
Assessment of methodological quality
Study quality was critically appraised using previously devel-
oped criteria for prognostic studies [15]. We assessed study
design, missing data and loss to follow-up (selection bias),
adequate description and measurement of imaging features
and outcome (information bias), reported effect size, treatment
of continuous risk predictors and multivariable adjustment for
possible confounders.
Data extraction and analysis
Study characteristics and hazard ratios (HRs) for all in-
vestigated CMR findings with accompanying 95 % con-
fidence intervals (CIs) were extracted using a standard-
ized form. Meta-analysis was performed for all CMR
findings investigated by three of more studies, using ran-
dom effect models. HRs for specific findings were
recalculated to one uniform clinically applicable number
of units change. Heterogeneity was assessed using
Cochran’s Q test and the I2 statistic [16]. CMR findings
investigated as dichotomous variables were additionally
presented in the corresponding forest plots. To determine
the effect of individual study data, sensitivity analyses
were performed by recalculating pooled HRs after ex-
cluding the results of one study. If study data were used
in multiple papers and the same CMR findings were
evaluated, only the study with the largest sample size
was selected, thus excluding the risk of using duplicate
data in our meta-analysis. The risk of publication bias
was assessed using visual inspection of funnel plots
and Egger’s test [17].
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Results
Search results
Through a systematic literature search in MEDLINE and
EMBASE and extensive reference cross-checking, 2,733 po-
tentially relevant records were retrieved, of which 2,610 were
excluded based on title and abstract. After full-text review of
the remaining 123 articles, 44 papers were finally selected, of
which eight studies in 539 patients described CMR findings
(Fig. 1) [18–25].
Study and patient characteristics of the included studies
are presented in Table 1. The studies were published be-
tween 2007 and 2014; study size ranged from 37 to 110
patients, mean age ranged from 39 to 62 years, and 60–
79 % of the population was female. The majority of pa-
tients were diagnosed with idiopathic PAH (41–100 %),
two studies included a subset of patients with congenital
heart disease (9 % and 24 %, respectively) [23, 25] and
one study included patients with PH group III, IV or V
(24 % of patients) [21]. Two studies did not report infor-
mation on the use of PAH-specific mediation [24, 25]; in
all other studies >60 % of patients were on PAH-specific
therapy at baseline.
The majority of studies used death (or transplant) as the
primary outcome; two studies used a composite outcome, ad-
ditionally including hospitalization for heart failure [21, 23].
Mean follow-up duration varied between 10 and 45 months,
and the primary outcome event occurred in 4–25 patients (10–
33 % of the study population).
Methodological aspects
The individual bias assessment per study is detailed in Table 2.
Five out of eight studies had a retrospective study design.
Information on missing values and loss to follow-up was not
reported in two studies. It is therefore important to recognize
the possible impact of selection bias.
Right heart catheterization was used for the diagnosis
of PAH in 100 % of the included patients. The majority
Fig. 1 PRISMA (Preferred
Reporting Items for Systematic
Reviews and Meta-Analyses)
2009 flow diagram. * One study
investigated both echocardio-
graphic and cardiac magnetic res-
onance imaging (CMR) findings.
PAH pulmonary arterial
hypertension
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of studies used short-axis segmentation for the measure-
ment of RV volumes [19–21, 23, 24]; one study used a
transverse segmenting method [22] and none of the stud-
ies used axial slice segmentation. Slice thickness varied
between 5 and 10 mm and temporal resolution between
20 and 25 frames/cycle or 35–45 ms. Two studies did
not report spatial or temporal resolution [19, 21]. None
of the studies explicitly described if the valvular planes
were taken into account in the segmentation and how the
tricuspid valve was delineated; however, most studies do
mention that both ventricles were covered from base to
apex. Most studies are not clear about the methodology
used for the selection of the trabeculae. The technical
details regarding the CMR acquisition and analysis are
described in more detail in Supplemental File 2.
Although all studies reported HRs using Cox regres-
sion analysis, large differences were found regarding the
type and number of predictors per event used in the mul-
tivariable analysis. Five studies performed some form of
multivariable adjustment, of which only one study adjust-
ed for age and sex. Only one study used ten or more
events per predictor. Because of this large variety between
studies and overall suboptimal methodological quality of
multivariable adjustment, it was decided to present only
univariable HRs in the forest plots.
Prognostic value of baseline CMR findings
Eight studies evaluated 21 different CMR findings, as shown
in Table 3. Meta-analysis was performed for nine CMR find-
ings that were evaluated by three or more studies. Forest plots
and pooled HRs are presented in Fig. 2. The strongest predic-
tor of mortality was RV ejection fraction: pooled HR 1.23
(95 % CI 1.07–1.41, p=0.003) per 5 % decrease. In addition,
RV end-diastolic volume index (p=0.049) and end-systolic
volume index (p = 0.013) and left ventricular (LV) end-
diastolic volume index (p=0.045) were of prognostic impor-
tance. Notably, measurements of RV and LV mass did not
provide prognostic information in PAH (p = 0.852 and
p=0.983, respectively).
Although RV stroke volume index as measured by the
summation of disks method did not have a significant
Table 3 Overview of investigated cardiac magnetic resonance imaging (CMR) findings per study
CMR finding Total
studies
(n)
Gan,
2007
[18]
Van
Wolferen,
2007 [19]
Van de
Veerdonk,
2011 [20]
Freed,
2012
[21]
Yamada,
2012
[22]
Cho,
2014
[23]
Swift,
2014
[24]
Swift ,
2014
[25]
RVejection fraction 6 xa xa x x x x
RVend-diastolic volume 5 xa xa x x x
RVend-systolic volume 4 xa x x x
RV stroke volume 3 x x x
PA flow stroke volume index 2 xa x
PA flow cardiac index 2 xa x
RV mass 3 xa x x
LVejection fraction 5 xa xa x x x
LVend-diastolic volume 5 xa xa x x x
LVend-systolic volume 4 xa x x x
LV stroke volume 2 xa x
LV mass 3 xa x x
RV wall thickness 1 xa
LV wall thickness 1 xa
Ventricular mass index (RV/LV mass) 1 x
RA volume 1 x
LA volume 1 x
PA relative area change 1 x
RV insertion points late gadolinium
enhancement
1 x
Full width at half maximum of the
bolus
passage
1 x
Pulmonary transit time 1 x
LV left ventricular, PA pulmonary artery, RV right ventricular
a Additional serial investigation of CMR finding (change between baseline and follow-up)
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prognostic value (pooled HR 1.05, p = 0.242) [21, 22,
24], the pulmonary artery (PA) flow stroke volume index
as measured by CMR phase-contrast imaging predicted
mortality in two studies [19, 24]. Less investigated CMR
measurements such as LV stroke volume [20, 24], pul-
monary artery relative area change [18], left atrial vol-
ume, late gadolinium enhancement at RV insertion points
[21] and two novel dynamic contrast-enhanced CMR
measurements (full width at half maximum of the bolus
passage and pulmonary transit time) [25] seem promising
but require further evaluation.
Serial CMR evaluation
Two studies included in this review additionally quantified the
individual change in specific CMR findings during a follow-
up period and directly associated these with patient outcomes.
Van Wolferen et al. [19] showed that overall mortality was
associated with a decrease in RV ejection fraction (p=0.015)
and PA flow stroke volume index (p=0.006) at 1-year follow-
up. Van de Veerdonk’s group [20] reported a 1-year change in
RV ejection fraction (p=0.014), RV end-diastolic and end-
systolic volume index (both p<0.001) as significant predic-
tors of long-term outcome.
Risk of bias assessment
A combination of visual assessment of funnel plots and
Egger’s [17] test did not provide statistical evidence for pub-
lication bias for any of the CMR findings included in the meta-
analysis. Statistical heterogeneity among studies was general-
ly low, as presented by Cochran’s Q and I2 statistics in Fig. 2
in the corresponding forest plots. We noted a discrepancy
between the values that were reported in the study by van
Fig. 2 Prognostic value of cardiac magnetic resonance imaging (CMR)
findings evaluated by three or more studies. Values are presented as mean
[95 % confidence interval]. EDVI end-diastolic volume index, EF
ejection fraction, ESVI end-systolic volume index, LV left ventricular,
MI mass index, RV right ventricular, SVI stroke volume index
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Wolferen et al. [19] compared to the other studies, as effect
sizes and standard errors were extremely large in this study.
We therefore conducted sensitivity analyses by excluding the
results of this study. This did not result in significantly differ-
ent HRs and did thus not change our conclusions.
Discussion
To our knowledge, this is the first systematic review and meta-
analysis that substantiates the clinical yield of CMR findings
in the prognostication of PAH patients. Among eight studies
(539 patients) that investigated 21 different CMR findings,
RV ejection fraction was found to be the strongest and most
well established predictor of mortality in PAH. In addition,
increased RV volumes and decreased LVend-diastolic volume
at baseline were found to be associated with a higher mortality
risk in PAH patients.
Right heart failure
The primary cause of death in PAH is right heart decompen-
sation [8]. This is congruent with the observation that a de-
crease in RV function is such an important prognostic factor,
as it indicates that the RV is no longer able to cope with the
high pulmonary pressures, leading to increased RV diastolic
pressures and RV dilatation. RV cardiac output as invasively
assessed during right heart catheterization has similarly shown
to predict mortality in PAH [7, 8]. Studies that have investi-
gated echocardiographic measurements of RV function, such
as TAPSE or RV longitudinal strain, report similar findings
[26, 27]. RVejection fraction assessed with equilibrium radio-
nuclide angiography also showed to be of prognostic impor-
tance [28]. Nevertheless, CMR is currently considered as the
reference standard for the assessment of RV volumes and
function [29]. RV function as measured with CMRmay there-
fore be the most accurate and thus most reliable predictor.
However, it has to be acknowledged that direct comparisons
between the different imaging modalities are not reported yet.
Ventricular-ventricular interaction
Whereas CMR-derived RV volumes are increased in high-risk
PAH patients, LV end-diastolic volume is decreased. Similar
results have been reported in several echocardiographic stud-
ies [30–32]. These findings emphasize even more the inextri-
cable connection between the two ventricles. Although often
considered as separate entities, the two ventricles share com-
monmyofibers, a noncompliant pericardium and of course the
interventricular septum [33]. The pressure-overloaded RVwill
alter LV geometry by a leftward septal shift, resulting in a D-
shaped LV, which is generally considered as one of the hall-
marks of pulmonary hypertension. This so-called systolic D-
sign is primarily an expression of RV pressure overload, in
contrast to a diastolic D-sign which is considered a sign of a
volume-overloaded RV [34]. Interestingly, previous studies
have shown that the diastolic leftward septal shift is associated
with mortality in PAH, in contrast to the systolic leftward
septal shift [35]. Accordingly, we found decreased LV end-
diastolic volume to be of prognostic value, in contrast to LV
end-systolic volume.
The overall observation that systolic LV geometry is not
associated with mortality may be explained by the fact that RV
systolic pressures are generally high in a stable PAH state.
However, once the RV starts to fail, LV preload will decrease
due to lower transpulmonary flow, and RV diastolic pressures
will rise. The accompanied altered diastolic LV geometry can
therefore be seen as a direct expression of RV failure [35].
Subsequently, this altered shape could impair LV filling and
function, further leading to increased pulmonary pressures,
which may create a vicious circle tilting a stable PAH state
towards clinical deterioration and, ultimately, death.
Serial measurements
Apart from baseline findings evaluated at the time of diagno-
sis, changes in several haemodynamic, functional, biochemi-
cal and imaging variables could carry incremental prognostic
information, as they conceivably better reflect an individual’s
course of disease [19, 20, 36, 37]. Thus far, only two studies
have directly related subject-specific changes in CMR mea-
surements to clinical outcome using Cox regression [19, 20].
Both studies report the prognostic importance of a decrease in
RVejection fraction over time. In addition, van de Veerdonk et
al. [38] recently published the results of repeated CMR mea-
surements during a follow-up period of 10 years in patients
with initially stable idiopathic PAH for 5 years. Although no
HRs were presented, this study showed that late disease pro-
gression is also accompanied by increased RV volumes and
decreased RVejection fraction.
RV mass
Based on three studies, our results showed that RV mass
does not provide prognostic information in PAH [19, 21,
22]. This is probably because concentric RV hypertrophy
is an adaptive response to increased RV pressures that
serves to maintain wall stress as low as possible, as is
also seen in the LV [39, 40].
RV mass-to-volume ratio allows the distinction between
RV concentric and eccentric hypertrophy, which might better
reflect the RV’s adaptive or maladaptive response. A recently
published cross-sectional study in patients with idiopathic
PAH showed that eccentric hypertrophy, reflected by a lower
RV mass-to-volume ratio, was clearly related to worse RV
systolic function, right ventricular to arterial coupling and
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clinical impairment [40]. Moreover, in patients with tetralogy
of Fallot, a lower RV mass-to-volume ratio was predictive of
death [41]. Therefore, it may be more prudent to focus on RV
mass-to-volume ratios rather than on RV mass alone.
Study limitations
Although we calculated pooled effect estimates in our review,
the results of the random effect models should be interpreted
with caution, as we included only univariable HRs in the
meta-analysis, due to the large variability between studies in
which multivariable adjustment was performed (regarding the
type and number of predictors per event used). Second, al-
though formal tests for publication bias yielded mainly non-
significant results, the relative lack of power of Egger’s test in
detecting publication bias for imaging findings investigated in
less than ten studies should be recognized. Theoretically, pub-
lication bias can cause under-reporting of non-significant
HRs, leading to a relative overestimation of the pooled HRs.
Finally, although differences within studies regarding the
CMR acquisition and analysis probably reflect the normal
variance in day-to-day practice, they may lead to less precise
measurements (independent of the outcome). While the vast
majority of the studies used short-axis segmentation, it has
been suggested that axial segmentation results in higher repro-
ducibility, as it may decrease the difficulty of valve delineation
in the basal slices [42, 43]. Incomplete segmentation of the
tricuspid plane, inaccurate delineation of the basal slice and
the methodology used to deal with the trabeculae can substan-
tially impact the measurements of RV volumes [44, 45]. The
subsequent ‘random noise’ would dilute the effect and thus
could cause a relative underestimation of the actual hazard
ratios.
Clinical implications
This review substantiates the clinical yield of specific
CMR findings in the identification of patients with
PAH at higher risk of clinical deterioration. This is im-
portant, as timely intensification of PAH-specific therapy
could prevent further clinical worsening and death. In
addition, CMR-derived RV ejection fraction could be of
additional value for the longitudinal assessment of PAH.
More research is needed to investigate the prognostic
value of other serial CMR measurements, and baseline
measurements such as RV mass-to-volume ratio, LV
stroke volume, pulmonary artery relative area change
and left atrial volume. In addition, it would be worth-
while to directly compare the prognostic value of RV
function measured using CMR with RV function mea-
sured using other non-invasive imaging modalities, such
as echocardiography.
Conclusion
CMR is useful and accurate in the prognostication of PAH
patients. RV ejection fraction at baseline and during follow-
up is the strongest and most well investigated predictor of
mortality in patients with PAH. In addition, increased RV
volumes and decreased LV end-diastolic volume are of prog-
nostic importance.
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